Anti cd133 1 apc or pe

Manufactured by Miltenyi Biotec

Anti-CD133/1-APC or PE is a laboratory reagent used for the detection and analysis of CD133/1-positive cells. It is a monoclonal antibody conjugated with either the fluorescent dyes APC (allophycocyanin) or PE (phycoerythrin). This reagent can be used in flow cytometry applications to identify and quantify CD133/1-expressing cells in various biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Attune nxt 4 laser cytometer, by Thermo Fisher Scientific (2 mentions) Dapi cat no d9564, by Merck Group (2 mentions) 4 6 diamidino 2 phenylindole (dapi), by Thermo Fisher Scientific (1 mentions) Epcam fitc, by Thermo Fisher Scientific (1 mentions) Ssea 1 apc, by Thermo Fisher Scientific (1 mentions) Facs influx, by BD (1 mentions) Anti cxcr4 apc, by Thermo Fisher Scientific (1 mentions) Cd44 pe, by Thermo Fisher Scientific (1 mentions) Facscanto 2, by BD (1 mentions)

3 protocols using anti cd133 1 apc or pe

Identification of Pancreatic Cancer Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary pancreatic cells (monolayers and spheres) were trypsinized and resuspended in Sorting Buffer (3 μM EDTA, and 3% FBS in 1X PBS). To identify CD133 positive CSC, the following conjugated antibodies were used: anti-CD133/1-APC or PE; (Miltenyi), and appropriate isotype-matched control antibodies. For autofluorescent detection, cells were excited with blue laser 488 nm and selected as the intersection with the filters 530/30 (BL1) and 590/40 (BL2) [20 (link)]. For all assays, 2 mg/mL DAPI (Cat no. D9564, Sigma-Aldrich) was used to exclude dead cells with laser VL1. Data were analyzed with FlowJo 9.3 software (Tree Star Inc., Ashland, OR.). Cytometry data was acquired with an Invitrogen™ Attune™ NxT 4-laser cytometer with software version 3.1.1.

Alors-Perez E., Blázquez-Encinas R., Alcalá S., Viyuela-García C., Pedraza-Arevalo S., Herrero-Aguayo V., Jiménez-Vacas J.M., Mafficini A., Sánchez-Frías M.E., Cano M.T., Abollo-Jiménez F., Marín-Sanz J.A., Cabezas-Sainz P., Lawlor R.T., Luchini C., Sánchez L., Sánchez-Hidalgo J.M., Ventura S., Martin-Hijano L., Gahete M.D., Scarpa A., Arjona-Sánchez Á., Ibáñez-Costa A., Sainz B J.r., Luque R.M, & Castaño J.P. (2021). Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Journal of Experimental & Clinical Cancer Research : CR, 40, 382.

+ Open protocol

+ Expand

Isolation and Analysis of Pancreatic Cancer Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary pancreatic cells (monolayers and spheres) were trypsinized and resuspended in Sorting Buffer (3 µM EDTA, and 3 % FBS in 1X PBS). To identify CD133 positive CSC, the following conjugated antibodies were used: anti-CD133/1-APC or PE; (Miltenyi), and appropriate isotype-matched control antibodies. For auto uorescent detection, cells were excited with blue laser 488 nm and selected as intersection with the lters 530/30 (BL1) and 590/40 (BL2) (20) . For all assays, 2 mg/mL DAPI (Cat no. D9564, Sigma) was used to exclude dead cells with laser VL1. Data were analyzed with FlowJo 9.3 software (Tree Star Inc., Ashland, OR.). Cytometry data was acquired with an Invitrogen™ Attune™ NxT 4-laser cytometer with software version 3.1.1.

Alors‐Pérez E., Blázquez‐Encinas R., Alcalá S., Viyuela-García C., Pedraza‐Arévalo S., Herrero‐Aguayo V., Jiménez‐Vacas J.M., Mafficini A., Sánchez‐Frías M., Cano M.T., Abollo‐Jiménez F., Marín-Sanz J.A., Cabezas-Sáinz P., Lawlor R.T., Luchini C., Sánchez L., Sánchez‐Hidalgo J.M., Ventura S., Martín-Hijano L., Gahete M.D., Scarpa A., Arjona‐Sánchez Á., Ibáñez‐Costa A., Sáinz B., Luque R.M., & Castaño J.P. (2021). Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.

+ Open protocol

+ Expand

Pancreatic Cancer Stem Cell Identification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary pancreatic cells (adherent monolayers or dissociated cells from sphere cultures) were resuspended in Sorting buffer (13 PBS; 3% FBS [v/v]; 3 mM EDTA [v/v]) before analysis or sorting with a FACS Canto II or FACS Influx instrument, respectively (BD). To identify pancreatic CSCs, the following antibodies were used: anti-CD133/1-APC or PE; (Miltenyi), anti-CXCR4-APC, SSEA-1-APC, EPCAM-FITC, CD44-PE (all from eBiosciences), or appropriate isotype-matched control antibodies. DAPI was used for exclusion of dead cells (eBiosciences). All samples were analyzed by flow cytometry using a FACS Canto II (BD), and data were analyzed with FlowJo 9.2 software (Tree Star).

Sancho P., Burgos-Ramos E., Tavera A., Bou Kheir T., Jagust P., Schoenhals M., Barneda D., Sellers K., Campos-Olivas R., Graña O., Viera C.R., Yuneva M., Sainz B J.r, & Heeschen C. (2015). MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell metabolism, 22(4).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!